Schistosomiasis is a helminthic infection and one of the neglected tropical diseases (NTDs). It is caused by blood flukes of the genus Schistosoma. It is an important public health problem, particularly in poverty-stricken areas, especially those within the tropics and subtropics. It is estimated th...at at least 236 million people worldwide are infected, 90% of them in sub-Saharan Africa, and that this disease causes approximately 300,000 deaths annually. The clinical manifestations are varied and affect practically all organs. There are substantial differences in the clinical presentation, depending on the phase and clinical form of schistosomiasis in which it occurs. Schistosomiasis can remain undiagnosed for a long period of time, with secondary clinical lesion. Here, we review the clinical profile of schistosomiasis. This information may aid in the development of more efficacious treatments and improved disease prognosis.
more
Training in monitoring and epidemiological assessment of mass drug administration for eliminating lymphatic filariasis: learners’ guide. World Health Organization.
Building on previous guidelines, the People In Aid Code seeks to offer agencies an effective framework for human resources management, helping them assess and raise their performance.
This position paper on polio vaccines replaces the 2016 WHO position paper, and summarizes recent developments in the field.
The WHO guidelines provide recommended steps for safe phlebotomy and reiterate accepted principles for drawing, collecting blood and transporting blood to laboratories/blood banks.
In the aftermath of the April 2015 earthquake in Nepal, this paper looks at lessons drawn from previous comparable disasters and seeks to provide invaluable information and assistance to the operational agencies responding to the crisis.
Update 2021; Immunization, Vaccines and Biologicals
Responding to a poliovirus event and outbreak, Part 1: General (SOPs) describes the general principles and steps to facilitate timely and effective responses to poliovirus events and outbreaks, and incorporate lessons learned from recent previous outbreak response efforts. This document summarizes r...oles and responsibilities of national governments and Global Polio Eradication Initiative (GPEI) partners.
Effective 01 November 2017 until 30 April 2018
more
BMC Res Notes (2016) 9:182 DOI 10.1186/s13104-016-1993-7
How to respond to, mitigate, and prevent risks to children’s protection and well-being is a profound, if unanswered, question. Practitioners agree that it is necessary to develop or strengthen protective factors at multiple levels, such as the family, community, and national levels.
On 15–16 December 2020, WHO and the Medicines for Malaria Venture co-convened a technical consultation to consider the preferred product characteristics (PPCs) for drugs used in malaria chemoprevention. The main goal of the technical consultation was to agree on the most important PPCs for drugs t...o protect populations from malaria (chemoprevention), while considering relevant measures of efficacy and the safety data needed to support WHO policy recommendations.
more
A Guide to Disaster Risk Reduction and Climate Change Adaptation
Financing Global Health 2016: Development Assistance, Public and Private Health Spending for the Pursuit of Universal Health Coverage presents a complete analysis of the resources available for health in 184 countries, with a particular focus on development assistance for health (DAH). DAH was estim...ated to total $37.6 billion in 2016, up 0.1% from 2015. After a decade of rapid growth from 2000 to 2010 (up 11.4% annually), DAH grew at only 1.8% annually between 2010 and 2016. In low-income countries, where much DAH is targeted, DAH made up 34.6% of total health spending in 2016. In upper-middle- and high-income countries, which generally do not receive DAH, DAH accounted for only 0.5% of total health spending. The other 99.5% of health spending – government, prepaid private, and out-of-pocket spending – is the subject of our further analysis.
more